Infinity Pharmaceuticals, Inc. (INFI) Short Interest Update
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 1,512,502 shares, a decrease of 55.8% from the June 15th total of 3,420,737 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average trading volume of 993,299 shares, the days-to-cover ratio is presently 1.5 days.
Several institutional investors have recently added to or reduced their stakes in INFI. Platinum Investment Management Ltd. raised its position in Infinity Pharmaceuticals by 62.6% in the first quarter. Platinum Investment Management Ltd. now owns 810,232 shares of the biotechnology company’s stock worth $2,617,000 after buying an additional 312,000 shares during the last quarter. Highbridge Capital Management LLC bought a new position in Infinity Pharmaceuticals during the first quarter worth $106,000. Citadel Advisors LLC raised its position in Infinity Pharmaceuticals by 19,074.1% in the first quarter. Citadel Advisors LLC now owns 86,522 shares of the biotechnology company’s stock worth $279,000 after buying an additional 86,978 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Infinity Pharmaceuticals during the first quarter worth $1,588,000. Finally, Geode Capital Management LLC raised its position in Infinity Pharmaceuticals by 4.5% in the first quarter. Geode Capital Management LLC now owns 345,366 shares of the biotechnology company’s stock worth $1,114,000 after buying an additional 15,005 shares during the last quarter. Institutional investors and hedge funds own 76.49% of the company’s stock.
A number of analysts recently commented on INFI shares. Zacks Investment Research cut Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. ValuEngine upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. Six investment analysts have rated the stock with a hold rating, Infinity Pharmaceuticals has an average rating of “Hold” and an average target price of $1.17.
Shares of Infinity Pharmaceuticals (NASDAQ INFI) opened at 1.38 on Friday. Infinity Pharmaceuticals has a 52-week low of $0.84 and a 52-week high of $3.84. The stock has a market cap of $69.61 million, a PE ratio of 690.00 and a beta of 2.63. The company’s 50-day moving average price is $1.78 and its 200-day moving average price is $2.11.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $19.60 million. The business’s quarterly revenue was down 99.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.82) EPS. On average, equities research analysts forecast that Infinity Pharmaceuticals will post ($0.84) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/16/infinity-pharmaceuticals-inc-infi-short-interest-update.html.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.